Dr. Henri Nico Doods has been chairman of hopeMed’s Scientific Council since early 2020 and before joining HopeMed, he was senior vice president and global director of Boehringer Ingelheim Research Beyond Borders Discovery’s Research Department. Doods has nearly 30 years of experience in medical studies and development, covering the fields cardiovascular, pain, obesity, CNS, breathing and other fields, has published more than 135 articles and has participated in the advancement of more than 15 compounds in clinical stages. .
“It is a great honor for the team that Henri joins HopeMed. As a leading expert in the global pharmaceutical industry, Henri has exceptional experience in pharmaceutical studies and development. Having Henri on board is a historic resolution for our company. According to the R pipe
Dr Doods said, ”In recent years, china’s biomedical industry has seized unprecedented opportunities and provides an incredibly dynamic environment for innovative, cutting-edge medical studies to satisfy patients’ desires. As a member of emerging national biopharmaceuticals, HopeMed has made encouraging progress in 2020. HopeMed, with a leading life sciences team, strong global intellectual property, as well as world-class clinical studies and partners and progression experts, has an exclusive product in a major portfolio with a prospective FiC HMI. 115, a prolactin anti-receptor antibody, has passed animal experiments and Phase I clinical studies in humans. Array and will participate in Phase II trials on multiple indications in 2021. I am pleased to enroll in this perfect superior prospective team, I am committed and motivated to facilitate the company’s built-in global Phase II clinical studies in Europe, the United States and China, and to advance strategic plans for the structure of a pipeline of high quality projects in the future.
About HopeMed
Hope Medicine Inc. is a science-driven, clinical-stage biopharmaceutical company with study bases and offices in Beijing, Shanghai and Nanjing, China. The company’s status quo is based on the deep understanding of the chart of translational medicine studies and decades of study effects from Professor Rui-Ping Xiao of the Institute of Molecular Medicine (IMM) at Peking University and his team. . Based on appropriate clinical studies and with the purpose of improving the quality of life, HopeMed is dedicated to the studies, progression and commercialization of first-class medicines for primary and non-unusual diseases that threaten human health. In early 2019, HopeMed finalized the investment circular and signed an exclusive international license agreement with Bayer AG on the progression and commercialization of a human antibody targeting the PRL receptor for the remedy of hair loss in humans and women, endometriosis and other chronic diseases with dysregulation PRL signaling. This antibody has shown adequate characteristics in animal models (including NHP models) and human protection tests. For the HMI-115, the company plans to launch a globally incorporated Phase II clinical examination in Europe, the United States, and China in 2021. At the same time, in reaction to unmet clinical needs, HopeMed established a diversified line through licenses and independent studies and progression of double drive models. In addition to HMI-115, based on circular rupture studies through Professor Xiao at IMM, the MG53 target drug will be carried through Peking University, which has demonstrated an intelligent curative effect in diabetes and animal models. of the diabetic foot.